Tyra Biosciences (TYRA) Income from Continuing Operations (2020 - 2026)
Tyra Biosciences (TYRA) posted Income from Continuing Operations of 363738000.0 for Q1 2026, down 968.75% on a QoQ basis from 34034000.0 in Q4 2025, and down 774.12% year-over-year from 53957612.3 in Q1 2025.
Tyra Biosciences (TYRA) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Tyra Biosciences' Income from Continuing Operations history runs 7 years deep, the most recent figure standing at 363738000.0 for Q1 2026.
- Quarterly Income from Continuing Operations fell 774.12% year-over-year to 363738000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 515558000.0 (down 89.85% YoY) and the FY2025 annual result came in at 306616000.0, down 154.92% from the prior year.
- Income from Continuing Operations was 363738000.0 for Q1 2026 at Tyra Biosciences, down from 34034000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 12962000.0 in Q4 2022 and bottomed at 363738000.0 in Q1 2026.
- A 5-year average of 69335588.24 and a median of 41894000.0 in 2025 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2025 — Income from Continuing Operations soared 44.54% — and 2026, when it tumbled 774.12%.
- Tyra Biosciences' Income from Continuing Operations stood at 12962000.0 in 2022, then tumbled by 76.13% to 22830000.0 in 2023, then retreated by 13.32% to 25871000.0 in 2024, then sank by 31.55% to 34034000.0 in 2025, then plunged by 968.75% to 363738000.0 in 2026.
- Business Quant data shows TYRA's Income from Continuing Operations at 363738000.0 in Q1 2026, 34034000.0 in Q4 2025, and 75892000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Tyra Biosciences | 1.90 Bn | 1.90 Bn | - | -363.74 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -363.74 Mn |
| Dec 31, 2025 | -34.03 Mn |
| Sep 30, 2025 | -75.89 Mn |
| Jun 30, 2025 | -41.89 Mn |
| Mar 31, 2025 | -41.61 Mn |
| Dec 31, 2024 | -25.87 Mn |
| Sep 30, 2024 | -135.01 Mn |
| Jun 30, 2024 | -69.07 Mn |
| Mar 31, 2024 | -75.03 Mn |
| Dec 31, 2023 | -22.83 Mn |
| Sep 30, 2023 | -61.13 Mn |
| Jun 30, 2023 | -70.61 Mn |
| Mar 31, 2023 | -67.78 Mn |
| Dec 31, 2022 | -12.96 Mn |
| Sep 30, 2022 | -31.32 Mn |
| Jun 30, 2022 | -15.17 Mn |
| Mar 31, 2022 | -34.75 Mn |
| Dec 31, 2021 | -9.93 Mn |
| Sep 30, 2021 | -44.68 Mn |
| Jun 30, 2021 | -5.60 Mn |